Bendell J.C.,Sarah Cannon Research Institute Tennessee Oncology PLLC |
Jones S.F.,Sarah Cannon Research Institute |
Hart L.,Florida Cancer Specialists SCRI |
Pant S.,University of Oklahoma |
And 8 more authors.
Cancer Investigation | Year: 2015
Background: This phase I study determined the maximum tolerated dose (MTD) of AUY922 with capecitabine in advanced solid tumors. Methods: Capecitabine 1000mg/m2 PO BID was administered with escalating doses of AUY922 IV; the MTD of AUY922 was combined with capecitabine 1250 mg/m2 (DL6). Results: 23 patients were treated at 5 dose levels (22 mg/m2-70 mg/m2). No DLTs were observed until DL6 (grade 3 diarrhea). Reversible vision darkening was seen in 26%. Four patients had partial response; 2 previously progressed on fluorouracil. Eight patients had stable disease (median 25.5 weeks). Conclusion: AUY922 plus capecitabine was well-tolerated up to 70mg/m2 with encouraging preliminary efficacy. Copyright © 2015 Taylor & Francis Group, LLC. Source